Jelena Lazovic1, Lea Guo1, Jonathan Nakashima1, Leili Mirsadraei1, William Yong1, Hyun J Kim1, Benjamin Ellingson1, Hong Wu1, Whitney B Pope1. 1. Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California (J.L., L.G., H.J.K., B.E., W.B.P.); Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (J.N., H.W.); Department of Pathology, University of California San Diego Medical Center, San Diego, California (L.M.); Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (W.Y.); Department of Biostatistics, Fielding School of Public Health and Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California (H.J.K.).
Abstract
BACKGROUND: Nitroxoline is an FDA-approved antibiotic with potential antitumor activity. Here we evaluated whether nitroxoline has antiproliferative properties on glioma cell growth in vitro and in vivo using glioma cell lines and a genetically engineered PTEN/KRAS mouse glioma model. METHODS: The effect of nitroxoline treatment on U87 and/or U251 glioma cell proliferation, cell-cycle arrest, invasion, and ability to induce an apoptotic cascade was determined in vitro. Magnetic resonance imaging was used to measure glioma volumes in genetically engineered PTEN/KRAS mice prior to and after nitroxoline therapy. Induction of apoptosis by nitroxoline was evaluated at the end of treatment using terminal deoxyribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end labeling (TUNEL). RESULTS: Nitroxoline inhibited the proliferation and invasion of glioblastoma cells in a time- and dose-dependent manner in vitro. Growth inhibition was associated with cell-cycle arrest in G1/G0 phase and induction of apoptosis via caspase 3 and cleaved poly(ADP-ribose) polymerase. In vivo, nitroxoline-treated mice had no increase in tumor volume after 14 days of treatment, whereas tumor volumes doubled in control mice. Histological examination revealed 15%-20% TUNEL-positive cells in nitroxoline-treated mice, compared with ∼5% in the control group. CONCLUSION: Nitroxoline induces apoptosis and inhibits glioma growth in vivo and in vitro. As an already FDA-approved treatment for urinary tract infections with a known safety profile, nitroxoline could move quickly into clinical trials pending confirmatory studies.
BACKGROUND:Nitroxoline is an FDA-approved antibiotic with potential antitumor activity. Here we evaluated whether nitroxoline has antiproliferative properties on glioma cell growth in vitro and in vivo using glioma cell lines and a genetically engineered PTEN/KRASmouseglioma model. METHODS: The effect of nitroxoline treatment on U87 and/or U251 glioma cell proliferation, cell-cycle arrest, invasion, and ability to induce an apoptotic cascade was determined in vitro. Magnetic resonance imaging was used to measure glioma volumes in genetically engineered PTEN/KRASmice prior to and after nitroxoline therapy. Induction of apoptosis by nitroxoline was evaluated at the end of treatment using terminal deoxyribonucleotidyl transferase (TDT)-mediated dUTP-digoxigenin nick end labeling (TUNEL). RESULTS:Nitroxoline inhibited the proliferation and invasion of glioblastoma cells in a time- and dose-dependent manner in vitro. Growth inhibition was associated with cell-cycle arrest in G1/G0 phase and induction of apoptosis via caspase 3 and cleaved poly(ADP-ribose) polymerase. In vivo, nitroxoline-treated mice had no increase in tumor volume after 14 days of treatment, whereas tumor volumes doubled in control mice. Histological examination revealed 15%-20% TUNEL-positive cells in nitroxoline-treated mice, compared with ∼5% in the control group. CONCLUSION:Nitroxoline induces apoptosis and inhibits glioma growth in vivo and in vitro. As an already FDA-approved treatment for urinary tract infections with a known safety profile, nitroxoline could move quickly into clinical trials pending confirmatory studies.
Authors: Whitney B Pope; Xin Joe Qiao; Hyun J Kim; Albert Lai; Phioanh Nghiemphu; Xi Xue; Benjamin M Ellingson; David Schiff; Dawit Aregawi; Soonmee Cha; Vinay K Puduvalli; Jing Wu; Wai-Kwan A Yung; Geoffrey S Young; James Vredenburgh; Dan Barboriak; Lauren E Abrey; Tom Mikkelsen; Rajan Jain; Nina A Paleologos; Patricia Lada; Michael Prados; Jonathan Goldin; Patrick Y Wen; Timothy Cloughesy Journal: J Neurooncol Date: 2012-03-18 Impact factor: 4.130
Authors: Joong Sup Shim; Yoshiyuki Matsui; Shridhar Bhat; Benjamin A Nacev; Jing Xu; Hyo-eun C Bhang; Surajit Dhara; Kee Chung Han; Curtis R Chong; Martin G Pomper; Alan So; Jun O Liu Journal: J Natl Cancer Inst Date: 2010-11-18 Impact factor: 13.506
Authors: T L Chenevert; L D Stegman; J M Taylor; P L Robertson; H S Greenberg; A Rehemtulla; B D Ross Journal: J Natl Cancer Inst Date: 2000-12-20 Impact factor: 13.506
Authors: Hongchao Jiang; Jori E Taggart; Xiaoxi Zhang; Doris M Benbrook; Stuart E Lind; Wei-Qun Ding Journal: Cancer Lett Date: 2011-07-06 Impact factor: 8.679
Authors: A Sobke; M Klinger; B Hermann; S Sachse; S Nietzsche; O Makarewicz; P M Keller; W Pfister; E Straube Journal: Antimicrob Agents Chemother Date: 2012-08-27 Impact factor: 5.191
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Bojana Mirković; Boštjan Markelc; Miha Butinar; Ana Mitrović; Izidor Sosič; Stanislav Gobec; Olga Vasiljeva; Boris Turk; Maja Čemažar; Gregor Serša; Janko Kos Journal: Oncotarget Date: 2015-08-07
Authors: Serena Veschi; Laura De Lellis; Rosalba Florio; Paola Lanuti; Alberto Massucci; Nicola Tinari; Michele De Tursi; Pierluigi di Sebastiano; Marco Marchisio; Clara Natoli; Alessandro Cama Journal: J Exp Clin Cancer Res Date: 2018-09-21
Authors: Matthew T Laurie; Corin V White; Hanna Retallack; Wesley Wu; Matthew S Moser; Judy A Sakanari; Kenny Ang; Christopher Wilson; Michelle R Arkin; Joseph L DeRisi Journal: mBio Date: 2018-10-30 Impact factor: 7.867